Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

General Pharmacology of Artesunate, a Commonly used Antimalarial Drug: Effects on Central Nervous, Cardiovascular, and Respiratory System

  • Lee, Hyang-Ae (Department of Pharmacological Research, Korea Institute of Toxicology, Korea Research Institute of Chemical Technology) ;
  • Kim, Ki-Suk (Department of Pharmacological Research, Korea Institute of Toxicology, Korea Research Institute of Chemical Technology) ;
  • Kim, Eun-Joo (Department of Pharmacological Research, Korea Institute of Toxicology, Korea Research Institute of Chemical Technology)
  • Received : 2010.04.01
  • Accepted : 2010.08.13
  • Published : 2010.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Artesunate, a semi-synthetic derivative of artemisinin, is used primarily as a treatment for malaria. Its effects on the central nervous system, general behavior, and cardiovascular, respiratory, and other organ systems were studied using mice, rats, guinea pigs, and dogs. Artesunate was administered orally to mice at doses of 125, 250, and 500 mg/kg and to rats and guinea pigs at 100, 200, and 400 mg/kg. In dogs, test drugs were administered orally in gelatin capsules at doses of 50, 100, and 150 mg/kg. Artesunate induced insignificant changes in general pharmacological studies, including general behavior, motor coordination, body temperature, analgesia, convulsion modulation, blood pressure, heart rate (HR), and electrocardiogram (ECG) in dogs in vivo; respiration in guinea pigs; and gut motility or direct effects on isolated guinea pig ileum, contractile responses, and renal function. On the other hand, artesunate decreased the HR and coronary flow rate (CFR) in the rat in vitro; however, the extent of the changes was small and they were not confirmed in in vivo studies in the dog. Artesunate increased hexobarbital-induced sleeping time in a dose-related manner. Artesunate induced dose-related decreases in the volume of gastric secretions and the total acidity of gastric contents, and induced increases in pH at a dose of 400 mg/kg. However, all of these changes were observed at doses much greater than clinical therapeutic doses (2.4 mg/kg in humans, when used as an anti-malarial). Thus, it can be concluded that artesunate is safe at clinical therapeutic doses.

Keywords

References

  1. Amold, K., Hien, T.T., Chinh, N.T., Phu, N.H. and Mai, P.P. (1990). A randomised comparative study of artemisinin (qinghaosu) suppositories and oral quinine in acute falciparum malaria. Trans. Roy. Soc. Trop. Med. Hyg., 84, 499-502. https://doi.org/10.1016/0035-9203(90)90012-4
  2. Bolli, R. (1991). Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc. Drugs. Ther., 5, 249-268. https://doi.org/10.1007/BF00054747
  3. Brewer, T.G., Grate, S.J., Peggins, J.O., Weina, P.J., Petras, J.M.,Levine, B.S., Heiffer, M.H. and Schuster, B.G. (1994a). Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg., 51, 251-259. https://doi.org/10.4269/ajtmh.1994.51.251
  4. Brewer, T.G., Peggins, J.O., Grate, S.J., Petras, J.M., Levine, B.S.,Weina, P.J., Swearengen, J., Heiffer, M.H. and Schuster, B.G.(1994b). Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg., 88, S33-S36.
  5. Brewer, T.G., Genovese, R.F., Newman, D.B. and Li, Q. (1998).Factors relating to neurotoxicity of artemisinin antimalarial drugs “listening to arteether”. Med. Trop. (Mars.), 58, 22-27.
  6. Cao, X.T., Bethell, D.B., Pham, T.P., Ta, T.T., Tran, T.N., Nguyen,T.T., Pham, T.T., Nguyen, T.T., Day, N.P. and White, N.J.(1997). Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Trans. Roy. Soc. Trop. Med. Hyg., 91, 335-342. https://doi.org/10.1016/S0035-9203(97)90099-7
  7. Carlini, E.A. (1973). Farmacologia Pratica sem Aparelhagem, Sarvier, Editorade Livros Medicos Ltd., Sao Paulo, 145-197
  8. as cited by Hellion-lbarrola et al., 1999. Journal of Ethnopharmacology 66, 271-276.는 기타
  9. Chen, H.H., Zhou, H.J. and Fang, X. (2003). Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res., 48, 231-236. https://doi.org/10.1016/S1043-6618(03)00107-5
  10. Classen, W., Altmann, B., Gretener, P., Souppart, C., Skelton-Stroud, P. and Krinke, G. (1999). Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs. Exp. Toxicol. Pathol., 51, 507-516. https://doi.org/10.1016/S0940-2993(99)80128-6
  11. Dell’Eva, R., Pfeffer, U., Vene, R., Anfosso, L., Forlani, A.,Albini, A. and Efferth, T. (2004). Inhibition of angiogenesis in vivo and growth of Kaposi’s sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol., 68, 2359-2366.
  12. Dunham, W.W. and Miya, T.S. (1957). A note on a simple apparatus of detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc., 10, 208-209.
  13. Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H. and Chitambar,C.R. (2001). The anti-malarial artesunate is also active against cancer. Int. J. Oncol., 18, 767-773.
  14. Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P.,Weber, H.O., Hengstler, J.G., Halatsch, M.E., Volm, M., Tew,K.D., Ross, D.D. and Funk, J.O. (2003). Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol., 64, 382-394. https://doi.org/10.1124/mol.64.2.382
  15. Ha, V., Nguyen, N.H., Tran, T.B., Bui, M.C., Nguyen, H.P., Tran,T.H., Phan, T.Q., Arnold, K. and Tran, T.H. (1997). Severe and complicated malaria treated with arteminisin, artesunate or artemether in Viet Nam. Trans. Roy. Soc. Trop. Med. Hyg., 91, 465-467. https://doi.org/10.1016/S0035-9203(97)90287-X
  16. Irwin, S. (1968). Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia (Berl.), 13, 222-257. https://doi.org/10.1007/BF00401402
  17. Koster, R., Anderson, M. and De Beer, E.J. (1959). Acetic acid for analgestic screening. Fed. Proc., 18, 412-418.
  18. Maude, R.J., Plewes, K., Faiz, M.A., Hanson, J., Charunwatthana, P., Lee, S.J., Tarning, J., Yunus, E.B., Hoque, M.G., Hasan, M.U., Hossain, A., Lindegardh, N., Day, N.P., White, N.J. and Dondorp, A.M. (2009). Dose artesunate prolong the electrocardiograph QT interval in patients with severe malaria?. Am. J. Trop. Med. Hyg., 80, 126-132.
  19. Michaelis, M., Kleinschmidt, M.C., Barth, S., Rothweiler, F., Geiler, J., Breitling, R., Mayer, B., Deubzer, H., Witt, O., Kreuter, J., Doerr, H.W., Cinatl, J. and Cinatl, J. Jr. (2010). Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem. Pharmacol., 79, 130-136. https://doi.org/10.1016/j.bcp.2009.08.013
  20. Park, B.K., O’Neill, P.M., Maggs, J.L. and Pirmohamed, M.(1998). Safety assessment of peroxide antimalarials: clinical and chemical perspectives. Br. J. Clin. Pharmacol., 46, 521-529.
  21. Price, R.N. (2000). Artemisinin drugs: novel antimalarial agents.Expert. Opin. Investig. Drugs., 9, 1815-1827. https://doi.org/10.1517/13543784.9.8.1815
  22. Ribeiro, I.R. and Olliaro, P. (1998). Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. (Mars.), 58, 50-53.
  23. Shay, H., Komarov, S.A., Fels, S.S., Meranze, D., Gruenstein, M.,and Siplet, H. (1945). A simple method for the uniform production of gastric ulceration in rats. Gastroenterology, 5, 43-61.
  24. Singh, N.P. and Lai, H. (2001). Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life. Sci., 70, 49-56. https://doi.org/10.1016/S0024-3205(01)01372-8
  25. Svensson, T.H. and Thieme, G. (1969). An investigation of a new instrument to measure motor activity of small animals. Psychopharmacologia (Berl.), 14, 157-163. https://doi.org/10.1007/BF00403689
  26. Swinyard, E.A., Brow, W.C. and Goodman, L.S. (1952). Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther., 106, 319-330.
  27. Truett, A.A. and West, D.B. (1995). Validation of a radiotelemetry system for continuous blood pressure and heart rate monitoring in dogs. Lab. Anim. Sci., 45, 299-302.
  28. Watts, J. and Maiorano, L. (1987). Effects of diltiazem upon globally ischemic rat hearts. Eur. J. Pharmacol., 138, 335-342. https://doi.org/10.1016/0014-2999(87)90471-7
  29. White, N.J. (2007). Cardiotoxicity of antimalarial drugs. Lancet.,7, 549-558. https://doi.org/10.1016/S1473-3099(07)70187-1
  30. oodbury, L.A. and Davenport, V.D. (1952). Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. Arch. Int. Pharmacodyn., 92, 97-107.

Cited by

  1. Toxicological profile and safety pharmacology of a single dose of fibroblast activation protein-α-based doxorubicin prodrug pp.0959-4973, 2018, https://doi.org/10.1097/CAD.0000000000000593